Site notifications

Sub menu

 
 

COVID-19 vaccine weekly safety report: 3 March 2021

Published

The national roll-out of COVID-19 vaccines commenced on 22 February 2021. The vaccine currently being supplied is Comirnaty BNT162b2 (mRNA), sponsored by Pfizer Australia Pty Ltd.

The Therapeutic Goods Administration (TGA) is closely monitoring suspected side effects (also known as adverse events) from the use of the vaccine.

Learn about the TGA’s COVID-19 vaccine safety monitoring and reporting activities or report a suspected side effect.

Total adverse event following immunisation (AEFI) reports received up to 28 February 2021

Gathering reports of suspected side effects following vaccination is just the first step in determining whether or not the effect is related to the vaccine and whether a significant safety issue is involved. Learn more about how the TGA identifies and responds to safety issues.

  • 2.3

    Reporting rate per 1000 doses

  • 79

    Total AEFI reports received

  • 33702

    Total doses administered

Reports by jurisdiction

  • 2

    Australian Capital Territory

  • 3

    Northern Territory

  • 5

    South Australia

  • 28

    Victoria

  • 34

    New South Wales

  • 4

    Queensland

  • 2

    Tasmania

  • 0

    Western Australia

  • 1

    Not reported

The most common reactions reported in the first week were:

  • Feeling faint
  • Dizziness
  • Headache
  • Nausea
  • Sweating

Evaluation of these reports is ongoing.

Adverse events reported to the TGA may not be caused by the vaccine. Learn more about causality.

Not all adverse events are reported, especially for minor and well-known side effects. Learn more about reporting levels.

The information the TGA receives in reports reflects the view of the reporter. As analysis of these reports is ongoing, the information may change as the data quality are reviewed or further information is provided. Total numbers may also change as duplicate reports are identified.

Active surveillance

AusVaxSafety is an active vaccine safety surveillance system that complements the TGA’s enhanced safety surveillance activities. Active vaccine safety surveillance uses SMS and a short survey to collect reports of AEFI directly from a subset of people receiving the vaccines. AusVaxSafety is an Australian Government-funded system that shares its findings with the TGA to assist our safety investigations and responses.

AusVaxSafety surveillance data to 28 February 2021:

There were 11,079 surveys sent in six of the eight states and territories, with 7397 people responding (67% response rate).

Of those who responded:

  • 64% reported no adverse event

  • 36% reported one or more adverse events

  • 0.7% reported visiting a doctor or emergency department as a result of their adverse event.

The most commonly reported reactions were:

  • injection site pain

  • fatigue

  • headache.

Useful links

Australian Government Department of Health COVID-19 vaccines hub

TGA COVID-19 vaccines hub

AusVaxSafety

Featured in

Related content

Help us improve the Therapeutic Goods Administration site